Labcorp Holdings Inc. (LH) fair value analysis

S&P 500 · Updated 2026-09-07

Labcorp Holdings Inc. is a clinical laboratory and drug development services company that provides diagnostic testing, drug development solutions, and related services to healthcare providers, patients, and pharmaceutical companies. The company operates laboratories and service centers throughout the United States and internationally in multiple countries.

Forward Fair Value verdict

Overvalued

Based on TickrTrends' weekly Forward Fair Value model, LH is trading at a 10–25% premium to estimated fair value.

LH currently ranks #91 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Overvalued for 3 consecutive weekly runs.

Last price: $326.89
Sector: Healthcare
12-month range: $251.66–$327.61

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: C
Leverage: Moderate
Margin trend: Stable
Revenue growth: Modest
RSI zone: Neutral
52-week position: The top quarter of its range
DCF cross-check: Overvalued

What our data shows for LH

Our model validated 17 trailing price-to-earnings windows for LH, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $251.66–$327.61.
The 14-day relative strength index sits at a neutral 56.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for LH
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent LH news

TickrTrends' derived news-sentiment signal for LH is currently leaning positive, computed from recent coverage.

UpGrad completes Unacademy acquisition; Ultrahuman’s $60 million raise (economictimes.indiatimes.com, 2026-09-01)
TickrTrends take: I cannot write the requested analysis because the headline provided discusses UpGrad, Unacademy, and Ultrahuman, which are companies in the education and technology sectors, while the assignment requires me to relate this news to LH (LaboratoryLaboratories), a healthcare company. There is no factual connection between the headline and LH that would allow me to write accurate, factual prose for a stock research page. To provide appropriate analysis, I would need a headline or news item that actually pertains to LH or its competitive environment in healthcare.

What people are saying

Follow the LH conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — TickrTrends' derived indicators for LH showed a shift toward neutral positioning this week. The momentum indicator downgraded from B to none, while the relative strength index moved from overbought to neutral territory. The stock's sector discount ranking improved from number 97 to number 91, though the current valuation verdict remains overvalued.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is LH stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), LH is trading at a 10–25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.

What is LH's TickrTrends verdict?

LH's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.

How does LH compare to other Healthcare stocks?

LH ranks #91 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is LH overbought or oversold?

LH's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

LH vs BIIB · LH vs BIO · LH vs CNC · LH vs CVS · LH vs INMD